Showing 741-750 of 4007 results for "".
Multi-Use Devices: Recommendations for Assessment and Selection
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/multi-use-devices-recommendations-for-assessment-and-selection/19214/Jason Pozner, MD offers insights on the selection and use of multi-use devices in practice.Selling Skin Care in Your Practice
https://practicaldermatology.com/topics/practice-management/selling-skin-care-in-your-practice/19294/While selling skin care products in your practice may seem like it has some disadvantages, Joel Schlessinger MD believes it's worth the extra work. During this video, Joel Schlessinger MD explains why he decided to sell products in his practice. Overall, he finds that selling items he recommends toTurning Acne Treatment Strategies Upside-Down
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/turning-acne-treatment-strategies-upside-down/54645/Julie Harper, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.Ensuring Equity for Your Patients
https://practicaldermatology.com/series/the-practical-dermatology-podcast/ensuring-equity-for-your-patients/54335/Jeanine Downie, MD, FAAD, and an expert panel discuss implicit bias and discrimination against various marginalized populations and how to be proactive in avoiding these problems in your practice. Joining Dr. Downie are Drs. Mona Gohara, Anthony Rossi, Jacob Beer, and Jane Yoo. This discussion is baEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/54612/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48959/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urThe Evolving Needs of the Modern Patient
https://practicaldermatology.com/series/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs."Ask Me Anything" Mentorship Session With Dr. DiAnne Davis
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/ask-me-anything-mentorship-session-with-dr-dianne-davis/39879/DiAnne Davis, MD, FAAD, discusses her career journey as a board-certified, fellowship trained cosmetic dermatologist with expertise in skin of color, laser and light-based procedures, neuromodulators, injectable fillers, platelet rich plasma (PRP), sclerotherapy, body contouring, acne scars, laser bDermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-socioeconomic-neighborhood-status-linked-with-hs-severity-plus-more/39881/This episode highlights new data linking neighborhood socioeconomic status to hidradenitis suppurativa severity, as well as a new study of mitochondrial decline in skin cells leading to skin aging and even obesity. Also, a new Atopic Dermatitis Journal Club examines combination therapy with dupiluma